- Nano Express
- Open Access
Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy
© to the authors 2008
- Received: 17 October 2008
- Accepted: 11 November 2008
- Published: 25 November 2008
Boron neutron capture therapy (BNCT) is increasingly being used in the treatment of several aggressive cancers, including cerebral glioblastoma multiforme. The main requirement for this therapy is selective targeting of tumor cells by sufficient quantities of10B atoms required for their capture/irradiation with low-energy thermal neutrons. The low content of boron targeting species in glioblastoma multiforme accounts for the difficulty in selective targeting of this very malignant cerebral tumor by this radiation modality. In the present study, we have used for the first time boron nitride nanotubes as carriers of boron atoms to overcome this problem and enhance the selective targeting and ablative efficacy of BNCT for these tumors. Following their dispersion in aqueous solution by noncovalent coating with biocompatible poly-l-lysine solutions, boron nitride nanotubes were functionalized with a fluorescent probe (quantum dots) to enable their tracking and with folic acid as selective tumor targeting ligand. Initial in vitro studies have confirmed substantive and selective uptake of these nanovectors by glioblastoma multiforme cells, an observation which confirms their potential clinical application for BNCT therapy for these malignant cerebral tumors.
- Boron nitride nanotubes
- Glioblastoma multiforme
- Boron neutron capture therapy
High-grade glioblastoma multiforme is uniformly fatal and largely unresponsive to all available treatments. Patients with these tumors usually survive for <1 year from the time of first diagnosis. Conventional surgical excision, generally limited to the main tumor mass, does not remove the microscopic foci of neoplastic cells that invade the surrounding normal brain substance beyond the main tumor mass, and are responsible for the inevitable tumor recurrence . Conventional radiotherapy cannot ablate completely these tumors , since this would require unacceptably high radiation doses that result in severe brain damage . Boron neutron capture therapy (BNCT) is a binary modality therapy that has the potential for effective treatment of many forms of cancers, including cerebral glioblastoma multiforme brain and melanomas [4–6]. BNCT is based on the neutron capture reaction, 10B(n, α)7Li, where a 10B atom captures a low-energy thermal neutron and spontaneously decays to produce the linear recoiling particles 4He (α particle) and 7Li. In tissues, these particles have short penetration ranges, approximately the width of a single cell (5 μm for 7Li and 9 μm for 4He). As the average linear energy transfer is high (7Li, 162 keV/μm; 4He, 196 keV/μm), this results in densely ionizing radiation restricted to the track of each particle [7, 8]. Thus, the essential requirement for effective BNCT is selective targeting of tumor cells with sufficient quantities of 10B atoms (15–30 μg/g or more) and their irradiation with low-energy thermal neutrons. In theory, BNCT is potentially capable of killing individual cancer cells while sparing the healthy normal parenchyma. Consequently, knowledge of the micro distribution of 10B from boronated drugs in cells of cancerous and normal tissues is of critical importance . The ideal drug would provide boron selectively to tumor cells and would be nontoxic to normal cells. Experimentally, cell culture tumor models provide a useful approach for the investigation and understanding the mechanisms of boron delivery by BNCT agents to cancer and normal cells [10, 11]. The problem, however, is that there is currently no truly satisfactory 10B target agent for any human tumor type  although several boron agents have been proposed and synthesized, but many of these have either one or more disqualifying features . The ability of BNCT to fulfill its clinical therapeutic potential thus clearly rests on the discovery and availability of effective and safe boron transport agents.
In the present preliminary study, we have investigated the use of boron nitride nanotubes (BNNTs) as boron atom carriers. BNNTs are structural analog of carbon nanotubes (CNTs) with alternating B and N atoms which entirely substitute for C atoms in a graphitic-like sheet with almost no change in atomic spacing. Thus, BNNTs are composed of a substantial number of boron atoms (about 50%) equivalents to hundreds to thousands per each nanotube. Hence our hypothesis underlying the present investigation is that BNNTs may serve as effective boron targets for BNCT. BNNTs have generated considerable interest within the scientific community by virtue of their unique properties. As with CNTs, they have various potentially useful structural and electronic applications [14, 15] and share good flexibility with CNTs with a Young modulus of 1.22 ± 0.24 TPa [16, 17] but have superior chemical and thermal stability. Together with their high resistance to oxidation and stability , these properties mark BNNTs as attractive potential candidates for a wide range of applications. Nevertheless, in sharp contrast to the many proposed biomedical applications of CNTs in recent years, e.g., biosensors, DNA chip, nanovectors for drug, protein and gene delivery , etc., the use of BNNTs in this field has been largely unexplored . Cytocompatibility studies and the interaction between BNNTs and living cells have only been reported recently [21, 22] by our group and other biomedical applications concerning their magnetic properties are actively under investigation in our laboratory.
In the present study, we realized stable dispersions of BNNTs employing a positively charged protein (ploy-l-lysine, PLL) as dispersion agent. Poly-l-lysine coated BNNTs were then conjugated with fluorescent molecules (quantum dots) to enable their tracking in living cells. Folic acid was used as a targeting ligand to functionalize BNNTs against tumor cells, because of the ease of the reaction procedure and the small size of the folate molecule, enabling a stable binding with the nanotube coating, thus permitting folate receptor-mediated endocytosis of PLL-BNNTs. To date, folate has been used as a targeting ligand for both tumor imaging and cancer chemotherapy [23–26].
The functionalized BNNTs were characterized by imaging, Z-potential, size distribution, and UV–Vis spectra. In vitro uptake tests were carried out on human glioblastoma multiforme cells and on healthy human primary fibroblasts as controls.
BNNT Dispersion and Functionalization
Boron nitride nanotubes provided by the Australian National University, Canberra, Australia, were produced by using a ball-milling and annealing method [27, 28]. These samples contain the 11B isotope. As the chemical and biological interactions are independent on the isotope type, we can assume the same results can be achieved with 10B containing (used in clinical BNCT). Details of sample purity and composition (provided by the supplier) are as follows: yield >80%, boron nitride >97 wt%, metal catalysts (Fe and Cr) derived from the milling process ~1.5 wt% and absorbed O2 ~1.5 wt%.
The polymer used for the aqueous suspension and dispersion of BNNTs was PLL obtained from Fluka (81339), MW 70,000–150,000. All experiments were carried out in phosphate buffered solution (PBS) as described previously [21, 22]. Briefly, samples of BNNT powder in a 0.1% PLL solution were ultrasonicated for 12 h with a Branson sonicator 2510 (Bransonic). The output power of sonicator was fixed at 20 W for all experiments. Next, the sample was centrifuged at 1,100×g for 10 min to remove nondispersed residuals and impurities. Excess PLL was removed by ultracentrifugation three times at 30,000×g for 30 min at 4 °C (Allegra 64R, Beckman) and stable PLL-BNNT dispersion was obtained as a result of the noncovalent coating of the nanotube walls with PLL.
Folate conjugation was achieved by linking the amino-groups of PLL with the γ carboxylic-groups of the folate molecules, which are not involved in the folate receptor interaction . Folic acid (F7876 from Sigma), 3.5, and 5 mM 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDC, 03450 from Fluka) were added to a dispersion of 50 μg/mL of PLL-BNNT . After reaction, the dispersion was ultracentrifuged (three times at 30,000×g for 30 min at 4 °C) to remove unbound folic acid and EDC resulting in stable dispersions of folate conjugated PLL-BNNT (F-PLL-BNNT).
Spectrophotometric analysis was carried out with a LIBRA S12 Spectrophotometer UV/Vis/NIR (Biochrom) to characterize the dispersions and to quantify BNNT concentrations .
Both the dispersed PLL-BNNTs and F-PLL-BNNTs were covalently labeled with carboxyl derivatised quantum dots for cellular tracking studies. Carboxyl quantum dots were supplied by Invitrogen (Qdot® 605 ITK™). The conjugation reaction between the amino-groups of PLL and carboxylic-groups of quantum dots was carried out as specified by the supplier. Briefly, 4 mL of PLL-BNNT (50 μg/mL) were mixed with 4 μL of Qdots (8 μM) and 60 μL of EDC, 10 mg/mL, as activator. The solution was gently stirred for 90 min at room temperature for optimal conjugation and finally centrifuged (1,000×g, 10 min) to remove large aggregates. Finally, ultracentrifugation (twice at 30,000×g for 30 min at 4 °C) was performed to remove unbound quantum dots and obtain the labeled BNNT dispersions. Even if quenching of quantum dot fluorescence can occur because of some electron transfer between BNNTs and fluorescence dyes , the final product results perfectly suitable for biological tracking .
Sample size distribution was analysed with an N4plus submicron particle size analyser (Beckman Coulter); Z-potential measurement was performed with a Nano Z-Sizer (Malvern Instrument). Each acquisition was performed three times on aqueous nanotube suspensions of concentration 1 μg/mL.
Cell Cultures and Viability Assay
Human glioblastoma multiforme T98G cells (ATCC CRL-1690) were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mMl-glutamine. Primary human gingival fibroblasts (gift from Dr. Stefania Moscato, University of Pisa) were cultured in the same medium with the addition of 10 ng/mL of epidermal growth factor (EGF). Cells were maintained at 37 °C in a saturated humidity atmosphere containing 95% air/5% CO2and were seeded in a 24-well plate (30,000 cells/well).
For viability testing, MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide, M-2128 from Sigma) cell proliferation assays were carried out after 24 h of incubation with PLL-BNNT and F-PLL-BNNT modified media, which contained 10% BNNT dispersion, corresponding to a final concentration of 10 μg/mL of BNNT. After trypsinization and counting with a Burker chamber, each cell culture was subdivided and seeded in six 96-well plate chambers. Once the adhesion was verified (after about 6 h from the seeding) cells were incubated with MTT 0.5 mg/mL for 2 h. After cell treatment with 100 μL of DMSO (dimethyl sulfoxide, D8418 from Sigma) absorbance at 550 nm was measured with a VERSAMax microplate reader (Molecular Devices). A reference control test (k-) was carried out.
Cellular Uptake Studies
After adhesion (at 6 h), the cells were treated for 90 min with the Qdots labeled PLL-BNNT and F-PLL-BNNT modified culture medium (final concentration 10 μg/mL of BNNTs). In a control experiment, folic acid was added to the cell culture medium to compete with the F-PLL-BNNTs. For this competitive inhibition experiment, folic acid was first added to the medium at a concentration of 3.5 mM and cells were incubated for 30 min. Subsequently, F-PLL-BNNTs were added and the cells were incubated for a further 90 min.
Lysosome tracking assays were carried out on glioblastoma cells with LysoTracker dye (L12491 from Invitrogen). This is a fluorescent acidotropic probe for labeling acidic organelles in live cells. The probe fluoresces when it accumulates in cellular compartments with low pH. For these studies, cells were incubated 2 h in a growth medium containing LysoTracker in a dilution of 1:2,500 after 90 min exposure to F-PLL-BNNT in the medium.
Cell imaging was carried out with a Nikon TE2000U fluorescent microscope equipped with a Nikon DS-5MC USB2 cooled CCD camera. The cellular uptake of labeled BNNT was determined by the fluorescence intensity obtained from the acquired images, and this provided a measure of the nanotubes concentration inside the cells. Before imaging, BNNT-incubated cells were washed three times with PBS buffer after each experiment.
Each image was analysed with a dedicated MatLab program for extrapolation of the fluorescence intensity. In particular, every color channel component (R,G,B) of the images was analysed. The average intensity of theR channel was then calculated and normalized to the maximum mean intensity obtained during all the experiments.
The results were analysed by analysis of variance (ANOVA) followed by Student’st test to establish statistical significance which was set at 5%. MTT tests were performed in sixplicate; while for fluorescence analysis six images were acquired for each experiment. In all cases, three independent experiments were carried out. Results are presented as mean value ± SEM.
Figure 1a shows a FIB image of dispersed BNNTs. Since the surface of many tumor cells over-expresses the folate receptor, while the surface of the normal cells exhibits only minimal expression, the folic acid functionalized PLL-BNNTs can be internalized by the tumor cells though the specific binding of the folic acid molecules present on the wall of the functionalized BNNTs with the surface folate receptors of the tumor cells. The basic idea of this concept is illustrated in Fig. 1b. A similar approach has been reported to enhance cellular uptake of CNTs .
Z-potential analysis confirmed the conjugation of folic acid with the PLL-BNNTs by revealing a strong positive Z-potential (43.4 ± 3.26 mV) for PLL-BNNTs; while a shift to −32.0 ± 2.51 mV was found for the F-PLL-BNNTs, thus indicating “masking” of the positive charges of PLL by the folate molecules.
The size distribution studies yielded an average value of 242 ± 92 nm for PLL-BNNTs and 479 ± 223 nm for the F-PLL-BNNTs.
In Vitro Experiments
The binding of the receptors and their ligands has the characteristics of specificity, selectivity, strong affinity, and obvious biological effect. Thus in the present study, we have demonstrated that PLL-coated BNNTs functionalized with the folate ligand enable targeted uptake of the nanotubes by tumor cells by receptor-mediated endocytosis.
Even if the cells of glioblastoma multiforme do not have the high level expression of folate receptors encountered in other cancers , their increased expression relative to normal brain cells is well documented  and there has been several reports in the literature on targeted drug delivery for this tumor based on folate ligands [34, 35]. The folate ligand used in the present study to functionalize BNNTs against tumor cells, is particularly attractive because of the relative ease of the reaction procedure and the small size of the folate molecule enabling a more stable binding to the nanotube noncovalent PLL coating.
In sharp contrast, fluorescence of glioblastoma cells was considerably weaker when the cells were incubated for 90 min in the presence of not folate-functionalized PLL-BNNTs (Fig. 4c; with Fig. 4d corresponding bright field image). Figure 4e demonstrates that the folate-mediated cellular uptake of F-PLL-BNNTs could be blocked by competitive inhibition if a large amount of free folate (3.5 mM) was added into the culture medium for 30 min before the addition of F-PLL-BNNTs (Fig. 4f is the corresponding bright field image).
Receptor-mediated endocytosis of F-PLL-BNNTs by glioblastoma multiforme cells is confirmed by Fig. 6b. This microphotograph consists of a high-magnification image of a glioblastoma cell following uptake of Qdot conjugated F-PLL-BNNTs and lysosomal tracking. Yellow fluorescence arises from merging of Qdot (red) and LysoTracker probe (green) and demonstrates therefore a strong accumulation of the nanovectors in the acidic compartments (lysosomes) of the cells.
The results of recent and ongoing clinical trials which confirm the safety of BNCT for the treatment of cerebral GBM highlight the immediate need for truly effective boron target agents [36, 37]. In the present s study, we have investigated the use of BNNTs as boron atom carriers. After their dispersion in biocompatible PLL solutions, BNNTs were functionalized with a fluorescent probe and with folic acid for tumor targeting.
The results obtained indicate that folate-functionalized BNNTs have the potential to act as a boron delivery agents to malignant glioblastoma cells as these preliminary in vitro studies have confirmed a strong and selective uptake of these nanotubes vectors by glioblastoma multiforme cells but not by normal human fibroblasts. Obviously extensive in vivo and preclinical tests are needed to explore the use of functionalized BNNTS as boron target agents for clinical BNCT .
The work described in this paper was supported in part by the Italian Institute of Technology (IIT) Network and the NINIVE (Non Invasive Nanotransducer for In Vivo gene therapy, STRP 033378) project, co-financed by the 6FP of the European Commission. The authors gratefully thank Mr. Carlo Filippeschi for allowing access to and use of the FIB microscope; Dr. Stefania Moscato (University of Pisa) for supplying the human primary fibroblasts and, finally, Prof. Shinji Takeoka and Mr. Yosuke Obata (Waseda University, Tokyo) for the size distribution and Z-potential analyses.
- Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. 1983, 58: 159–169. COI number [1:STN:280:DyaL3s%2FosV2ktQ%3D%3D] 10.3171/jns.1983.58.2.0159View ArticleGoogle Scholar
- Halperin AC, Bruger PC, Bullard DE: The fallacy of the localized supratentorial malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 1988, 15: 505–509. COI number [1:STN:280:DyaL1c3pvVemsw%3D%3D] 10.1016/S0360-3016(98)90036-0View ArticleGoogle Scholar
- Sullivan FJ, Hersher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, et al.: National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 1994, 30: 583–590. COI number [1:STN:280:DyaK2M%2FhtlGisw%3D%3D]View ArticleGoogle Scholar
- Barth RF, Soloway AH, Fairchild RG: Boron neutron capture therapy for cancer. Sci. Am. 1990, 263: 100–106. COI number [1:CAS:528:DyaK3MXhtlyqtrw%3D] 10.1038/scientificamerican1090-100View ArticleGoogle Scholar
- Coderre JA, Morris GM: The radiation biology of boron neutron capture therapy. Radiat. Res. 1999, 151: 1–18. COI number [1:CAS:528:DyaK1MXjslahtA%3D%3D] 10.2307/3579742View ArticleGoogle Scholar
- Sweet WH: The use of nuclear disintegration in the diagnosis and treatment of brain tumor. N. Engl. J. Med. 1951, 245: 875–878. COI number [1:CAS:528:DyaG38XjtlGjsQ%3D%3D]View ArticleGoogle Scholar
- Barth RF, Soloway AH, Fairchild RG, Brugger RM: Boron neutron capture therapy for cancer: Realities and prospects. Cancer 1992, 70: 2995–3007. COI number [1:STN:280:DyaK3s%2Fot1Kntg%3D%3D] 10.1002/1097-0142(19921215)70:12<2995::AID-CNCR2820701243>3.0.CO;2-#View ArticleGoogle Scholar
- Kobayashi T, Kanda K: Analytical calculation of boron-10 dosage in cell nucleus of neutron capture therapy. Radiat. Res. 1982, 91: 77–94. COI number [1:STN:280:DyaL383kvVGlsw%3D%3D] 10.2307/3575817View ArticleGoogle Scholar
- Gabel D, Foster S, Fairchild RG: The Monte Carlo simulation of the biological effect of the 10B(n, α)7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat. Res. 1987, 111: 14–25. COI number [1:CAS:528:DyaL2sXkslenur4%3D] 10.2307/3577018View ArticleGoogle Scholar
- Capala J, Makar JS, Coderre JA: Accumulation of boron in malignant and normal cells incubated in vitro with boronophenylalanine, mercaptoborane or boric acid. Radiat. Res. 1996, 146: 554–560. COI number [1:CAS:528:DyaK28Xms1Grtr0%3D] 10.2307/3579556View ArticleGoogle Scholar
- Panov P, Salomon Y, Kabalka GW, Bendel P: Uptake and washout of borocaptate sodium and borono-phenylalanine in cultured melanoma cells: a multi-nuclear NMR study. Radiat. Res. 2000, 154: 104–112. COI number [1:CAS:528:DC%2BD3cXks1Oju7c%3D] 10.1667/0033-7587(2000)154[0104:UAWOBS]2.0.CO;2View ArticleGoogle Scholar
- Hawthorne MF, Lee MW: A critical assessment of boron target compounds for boron neutron capture therapy. J. Neurooncol. 2004, 62: 33–45.Google Scholar
- Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem. Rev. 1998, 98: 1515–1562. COI number [1:CAS:528:DyaK1cXjtlygtL8%3D] 10.1021/cr941195uView ArticleGoogle Scholar
- Hamada N, Sawada SI, Oshiyama A: New one-dimensional conductors: graphitic microtubules. Phys. Rev. Lett. 1992, 68: 1579–1581. COI number [1:CAS:528:DyaK38XhsF2hs7k%3D]; Bibcode number [1992PhRvL..68.1579H] 10.1103/PhysRevLett.68.1579View ArticleGoogle Scholar
- Terrones M, Romo-Herrera JM, Cruz-Silva E, López-Urías F, Muñoz-Sandoval E, Velázquez-Salazar JJ, Terrones H, Bando Y, Golberg D: Pure and doped boron nitride nanotubes. Mater. Today 2007, 10: 30–38. COI number [1:CAS:528:DC%2BD2sXmt1Squrw%3D] 10.1016/S1369-7021(07)70077-9View ArticleGoogle Scholar
- Chopra NG, Zettl A: Measurement of the elastic modulus of a multi-wall boron nitride nanotube. Solid State Commun. 1998, 105: 297–300. COI number [1:CAS:528:DyaK1cXmsV2juw%3D%3D]; Bibcode number [1998SSCom.105..297C] 10.1016/S0038-1098(97)10125-9View ArticleGoogle Scholar
- Suryavanshi AP, Yu MF, Wen J, Tang C, Bando Y: Elastic modulus and resonance behavior of boron nitride nanotubes. Appl. Phys. Lett. 2004, 84: 2527–2529. COI number [1:CAS:528:DC%2BD2cXivVaqsLc%3D]; Bibcode number [2004ApPhL..84.2527S] 10.1063/1.1691189View ArticleGoogle Scholar
- Chen Y, Zou J, Campbell SJ, Le Caer G: Boron nitride nanotubes: Pronounced resistance to oxidation. Appl. Phys. Lett. 2004, 84: 2430–2432. COI number [1:CAS:528:DC%2BD2cXis1Wmu78%3D]; Bibcode number [2004ApPhL..84.2430C] 10.1063/1.1667278View ArticleGoogle Scholar
- Lacerda L, Bianco A, Prato M, Kostarelos K: Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv. Drug Deliv. Rev. 2006, 58: 1460–1470. COI number [1:CAS:528:DC%2BD28Xht1KmtLbN] 10.1016/j.addr.2006.09.015View ArticleGoogle Scholar
- Golberg D, Bando Y, Tang C, Zhi C: Boron nitride nanotubes. Adv. Mater. 2007, 19: 2413–2432. COI number [1:CAS:528:DC%2BD2sXhtFGhtbfF] 10.1002/adma.200700179View ArticleGoogle Scholar
- G. Ciofani, V. Raffa, A. Menciassi, P. Dario, Preparation of boron nitride nanotubes aqueous dispersions for biological applications. J. Nanosci. Nanotechnol. (2008). doi:10.1166/jnn.2008.339Google Scholar
- Ciofani G, Raffa V, Menciassi A, Cuschieri A: Cytocompatibility, interactions and uptake of polyethyleneimine-coated boron nitride nanotubes by living cells: confirmation of their potential for biomedical applications. Biotechnol. Bioeng. 2008, 101: 850–858. COI number [1:CAS:528:DC%2BD1cXht1Clt7zN] 10.1002/bit.21952View ArticleGoogle Scholar
- Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC: Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magnetic Resonance Materials in Physics. Biol. Med. (Paris) 2001, 12: 104–113. COI number [1:CAS:528:DC%2BD3MXkslCnt7Y%3D]Google Scholar
- Lu YJ, Low PS: Immunotherapy of folate receptor-expressing tumors: Review of recent advances and future prospects. J. Control Release 2003, 91: 17–29. COI number [1:CAS:528:DC%2BD3sXmsVSktLw%3D] 10.1016/S0168-3659(03)00215-3View ArticleGoogle Scholar
- Choi H, Choi SR, Zhou R, Kung HF, Chen IW: Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 2004, 11: 996–1004. 10.1016/j.acra.2004.04.018View ArticleGoogle Scholar
- Shen D, Pastan I, Gottesman MM: Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res. 1998, 58: 268–275. COI number [1:CAS:528:DyaK1cXntF2iug%3D%3D]Google Scholar
- Chen Y, Fitz Gerald J, Williams JS, Bulcock S: Synthesis of boron nitride nanotubes at low temperatures using reactive ball milling. Chem. Phys. Lett. 1999, 299: 260–264. COI number [1:CAS:528:DyaK1MXivVaisQ%3D%3D]; Bibcode number [1999CPL...299..260C] 10.1016/S0009-2614(98)01252-4View ArticleGoogle Scholar
- Yu J, Chen Y, Wuhrer R, Liu Z, Ringer SP: In situ formation of BN nanotubes during nitriding reactions. Chem. Mater. 2005, 17: 5172–5176. COI number [1:CAS:528:DC%2BD2MXpsFarurw%3D] 10.1021/cm050966fView ArticleGoogle Scholar
- Pan J, Feng SS: Targeted delivery of paclitaxel using folate-decorated poly(lactide)evitamin E TPGS nanoparticles. Biomaterials 2008, 29: 2663–2672. COI number [1:CAS:528:DC%2BD1cXksFKqsLk%3D] 10.1016/j.biomaterials.2008.02.020View ArticleGoogle Scholar
- Shi Kam NW, Connell M, Wisdom JA, Dai H: Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. USA 2005, 102: 11600–11605. COI number [1:CAS:528:DC%2BD2MXpsFGgsbs%3D]; Bibcode number [2005PNAS..10211600S] 10.1073/pnas.0502680102View ArticleGoogle Scholar
- Huang Q, Sandanayaka ASD, Bando Y, Zhi CY, Ma RZ, Shen GZ, Golberg D, Zhao JC, Araki Y, Ito O, Gao L: Donor–acceptor nanoensembles based on boron nitride nanotubes. Adv. Mater. 2007, 19: 934–938. COI number [1:CAS:528:DC%2BD2sXksFSlsb8%3D] 10.1002/adma.200602058View ArticleGoogle Scholar
- Raffa V, Castrataro P, Menciassi A, Dario P: Introduction to focused ion beam. In Applied scanning probe methods. Edited by: Bushan B, Fuchs H. Springer-Verlag, Heidelberg; 2005:357–407.Google Scholar
- Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Kamen BA: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992, 52: 3396–3401. COI number [1:CAS:528:DyaK38XksVGltLo%3D]Google Scholar
- Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV: Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control Release 2003, 92: 49–67. COI number [1:CAS:528:DC%2BD3sXnt1SntLg%3D] 10.1016/S0168-3659(03)00295-5View ArticleGoogle Scholar
- K.M. McNeeley, A. Annapragada, R.V. Bellamkonda, Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 18, 385101 (11 pp) (2007)Google Scholar
- Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, Backer JM: Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med. Chem. 2006, 6: 167–184. COI number [1:CAS:528:DC%2BD28XislOkurw%3D] 10.2174/187152006776119153View ArticleGoogle Scholar
- Jain KK: Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev. Neurother. 2007, 7: 363–372. COI number [1:CAS:528:DC%2BD2sXkt1Wru7Y%3D] 10.1586/1473722.214.171.1243View ArticleGoogle Scholar
- G. Ciofani, V. Raffa, A. Menciassi, A. Cuschieri, Boron nitride nanotubes: an innovative tool for nanomedicine. Nano Today 4, 8–10 (2009). doi:10.1016/j.nantod.2008.09.001View ArticleGoogle Scholar